Nanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsRigo, Lucas A
Carvalho-Wodarz, Cristiane S
Pohlmann, Adriana R
Guterres, Silvia S
Lehr, Claus Michael
Beck, Ruy C R
MetadataShow full item record
AbstractThe anti-inflammatory effect of polymeric deflazacort nanocapsules (NC-DFZ) was investigated, and possible improvement of epithelial barrier function using filter grown monolayers of A549 and Calu-3 using as models was assessed. NC prepared from poly(ε-caprolactone) (PCL) had a mean size around 200 nm, slightly negative zeta potential (∼ - 8 mV), and low polydispersity index (< 0.10). Encapsulation of DFZ had an efficiency of 85%. No cytotoxic effects were observed at particle concentration of 9.85 x 10(11) NC/ml, which was therefore chosen to evaluate the effect of NC-DFZ at 1% (w/v) of PCL and 0.5% (w/v) of DFZ on the epithelial barrier function of Calu-3 monolayers. Nanoencapsulated drug at 0.5% (w/v) increased transepithelial electrical resistance and decrease permeability of the paracellular marker sodium fluorescein, while non-encapsulated DFZ failed to improve these parameters. Moreover, NC-DFZ reduced the lipopolysaccharide (LPS) mediated secretion of the inflammatory marker IL-8. In vitro dissolution testing revealed controlled release of DFZ from nanocapsules, which may explain the improved effect of DFZ on the cells. These data suggest that nanoencapsulation of pulmonary delivered corticosteroids could be advantageous for the treatment of inflammatory conditions, such as asthma and chronic obstructive pulmonary diseases.
CitationNanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines. 2017 Eur J Pharm Biopharm
AffiliationHelmholtz-Institut für Pharmazeutische Forschung Saarland [HIPS], Universitätscampus E8.1, 66123 Saarbrücken, Germany.
JournalEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
- Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions.
- Authors: Lenz AG, Stoeger T, Cei D, Schmidmeir M, Semren N, Burgstaller G, Lentner B, Eickelberg O, Meiners S, Schmid O
- Issue date: 2014 Oct
- Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-β<sub>1</sub> in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in idiopathic pulmonary fibrosis.
- Authors: Togami K, Yamaguchi K, Chono S, Tada H
- Issue date: 2017 Jul
- SCC4 cell monolayers as an alternative sublingual barrier model: influence of nanoencapsulation on carvedilol transport.
- Authors: Dos Santos Chaves P, Visioli F, Buffon A, Raffin Pohlmann A, Stanisçuaski Guterres S, Beck RCR
- Issue date: 2019 Jan
- Beclomethasone Dipropionate-Loaded Polymeric Nanocapsules: Development, In Vitro Cytotoxicity, and In Vivo Evaluation of Acute Lung Injury.
- Authors: Chassot JM, Ribas D, Silveira EF, Grünspan LD, Pires CC, Farago PV, Braganhol E, Tasso L, Cruz L
- Issue date: 2015 Jan
- Isolation and characterization of a degradation product of deflazacort.
- Authors: Paulino AS, Rauber G, Deobald AM, Paulino N, Sawaya AC, Eberlin MN, Cardoso SG
- Issue date: 2012 Jun